Boston Scientific Announces FDA Approval and U.S. Launch of PROMUSŪ 2.25 mm Everolimus-Eluting Coronary Stent System

Wednesday, May 25, 2011 General News
Email Print This Page Comment
Font : A-A+

Boston Scientific becomes the first and only company to offer two distinct drug-eluting stents to treat small vessels

CONTACT:

Erik Kopp

508-650-8660 (office)

Media Relations

Boston Scientific Corporation

erik.kopp@bsci.com

Sean Wirtjes

508-652-5305 (office)

Investor Relations

Boston Scientific Corporation

investor_relations@bsci.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook